Biologic therapies in the vasculitides

Current Opinion in Rheumatology

Volumn 15, Issue 1, 2003, Pages 3-10

  Langford, Carol A ^a   Sneller, Michael C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AUTOANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB;

ADVERSE DRUG REACTION; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; DEMYELINATING DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; FLU LIKE SYNDROME; GIANT CELL ARTERITIS; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; LISTERIOSIS; LYMPHOCYTOPENIA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PATHOGENESIS; PNEUMOCONIOSIS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEPSIS; SUICIDAL BEHAVIOR; TUBERCULOSIS; TUMOR LYSIS SYNDROME; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; VASCULITIS;

EID: 0037214397     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200301000-00002     Document Type: Review

References (66)

1. Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44:1977-1983.
2. Sicotte NL, Voskuhl RR: Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
3. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465.
4. van Oosten BW, Barkhof F, Truyen L, et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
5. Fisher CJ, Jr., Agosti JM, Opal SM, et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996, 334:1697-1702.
6. Brion PH, Mittal-Henkle A, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999, 131;634.
7. McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002, 41:116-117.
8. Galaria NA, Werth VP, Schumacher HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000, 27:2041-2044.
9. Dereure O, Navarro R, Rossi JF, et al.: Rituximab-induced vasculitis. Dermatology 2001, 203:83-84.
10. Sheller MC, Fauci AS: Pathogenesis of vasculitis syndromes. Med Clin North Am 1997, 81:221-242.
11. Sneller MC: Granuloma formation, implications for the pathogenesis of vasculitis. Cleve Clin J Med 2002, 69:S1140-43.
12. Weyand CM, Hicok KC, Hunder GG, et al.: Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994, 121:484-491.
13. Weyand CM, Schonberger J, Oppitz U, et al.: Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994, 179:951-960.
14. Ludviksson BR, Sneller MC, Chua KS, et al.: Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10. J Immunol 1998, 160:3602-3609.
15. Csernok E, Trabandt A, Müller A, et al.: Cytokine profiles in Wegener's granulomatosis: Predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999, 42:742-750.
16. Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998, 41:1521-1537.
17. Cacoub P, Costedoat-Chalumeau N, Lidove O, et al.: Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002, 14:29-35.
18. Agnello V, Romain PL: Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheum Dis Clin North Am 1996, 22:1-21.
19. Mathieson PW, Cobbold SP, Hale G, et al.: Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 1990, 323:250-254.
20. Lockwood CM, Thiru S, Isaacs JD, et al.: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993, 341:1620-1622.
21. Lockwood CM, Thiru S, Stewart S, et al.: Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996, 89:903-912.
22. Jayne DRW: CAMPATH-1H (anti-CD-52) for refractory vasculitis: Retrospective Cambridge experience 1989-1999. Cleve Clin J Med 2002, 69 (suppl):S11-129.
23. Stone JH, Uhlfelder ML, Hellmann DB, et al.: Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001, 44:1149-1154. Open-label phase I study of etanercept in 20 patients with Wegener granulomatosis. Etanercept was well tolerated, although no conclusions can be drawn regarding efficacy.
24. Specks U, Fervenza FC, McDonald TJ, et al.: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840. An interesting case report of a patient with cANCA-positive Wegener granulomatosis treated with rituximab. The findings from this report raise important questions regarding the longevity of ANCA-producing plasma cells and the potential utility of this agent.
25. Cantini F, Niccoli L, Salvarani C, et al.: Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. Arthritis Rheum 2001, 44:2933-2935. Concise communication describing four patients with active giant cell arteritis treated with infliximab, of whom three experienced remission.
26. Airo P, Antonioli CM, Vianelli M, et al.: Anti-tumor necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002, 41:347-349.
27. Tatsis E, Schnabel A, Gross WL: Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998, 129:370-374. Series of four patients with Churg-Strauss syndrome who were treated with IFN-α. Three patients benefited from treatment, and in the remaining patient, IFN-α maintained remission induced by cyclophosphamide and prednisolone.
28. Termeer CC, Simon JC, Schopf E: Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 2001, 137:136-138.
29. Vassilopoulos D, Calabrese LH: Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002, 46:585-597.
30. Bonomo L, Casato M, Afeltra A, et al.: Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987, 83:726-730.
31. Casato M, Lagana B, Antonelli G, et al.: Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991, 78:3142-3147.
32. Migliaresi S, Tirri G: Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13 Suppl 13:S175-180.
33. Cresta P, Musset L, Cacoub P, et al.: Response to interferon alpha treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 1999, 45:122-128.
34. Mazzaro C, Lacchin T, Moretti M, et al.: Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995, (13 suppl) 13:S181-185.
35. Casato M, Agnello V, Pucillo LP, et al.: Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997, 90:3865-3873.
36. Pellicano R, Marietti G, Leone N, et al.: Mixed cryoglobulinemia associated with hepatitis C virus infection: A predictor factor for treatment with interferon? J Gastroenterol Hepatol 1999, 14:1108-1111.
37. Cohen P, Nguyen QT, Deny P, et al.: Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne 1996, 147:81-86.
38. Polzien F, Schott P, Mihm S, et al.: Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 1997, 27:63-71.
39. Calleja JL, Albillos A, Moreno-Otero R, et al.: Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia. Aliment Pharmacol Ther 1999, 13:1179-1186.
40. Misiani R, Bellavita P, Fenili D, et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994, 330:751-756. Randomized controlled trial examining interferon-α in patients with active hepatitis C associated cryoglobulinemic vasculitis. This study supports the efficacy of this treatment as well as the association of cryoglobulinemic vasculitis with hepatitis C viremia.
41. Ferri C, Marzo E, Longombardo G, et al.: Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial. Blood 1993, 81:1132-1136. Randomized crossover trial in which patients with hepatitis C associated cryoglobulinemic vasculitis were assigned to 2 groups with or without IFN-α. This agent improved the vasculitic manifestations but clinical and virologic rebound occurred after discontinuation.
42. Dammacco F, Sansonno D, Han JH, et al.: Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study. Blood 1994, 84:3336-3343. The efficacy of IFN-α versus and 6-methyl-prednisolone alone and together in patients with hepatitis C associated cryoglobulinemic vasculitis was examined in a randomized prospective trial. This trial confirmed the efficacy of IFN-α in this disease and provided the only prospective data to date regarding the effect of glucocorticoids.
43. Donada C, Crucitti A, Donadon V, et al.: Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 1998, 92:2983-2984.
44. Zuckerman E, Keren D, Slobodin G, et al.: Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and IFN-alpha. J Rheumatol 2000, 27:2172-2178.
45. Zaja F, Russo D, Fuga G, et al.: Rituximab for the treatment of type II mixed cryoglobulinemia. Hematologica 1999, 84:1157-1158. Case report of a patient with hepatitis C associated cryoglobulinemic vasculitis treated with rituximab. The mechanism of action of this agent in relation to the pathophysiology of disease warrants further cautious study.
46. Guillevin L, Lhote F, Sauvaget F, et al.: Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994, 53:334-337. Open label prospective trial of 6 patients with hepatitis B associated polyarteritis nodosa treated with IFN-α and plasma exchange together with prednisone if indicated for severe disease. This trial supports the importance of anti-viral therapy in the treatment of hepatitis B associated polyarteritis nodosa.
47. Avsar E, Savas B, Tozun N, et al.: Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998, 28:525-526.
48. Simsek H, Telatar H: Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol 1995, 20:263-265.
49. Duzova A, Bakkaloglu A, Yuce A, et al.: Successful treatment of polyarteritis nodosa with interferon alpha in a nine-month old girl. Eur J Pediatr 2001, 160:519-520.
50. Deleaval P, Stadler P, Descombes E, et al.: Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: Successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol 2001, 20:290-292.
51. Erhardt A, Sagir A, Guillevin L, et al.: Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. J Hepatol 2000, 33:677-683.
52. Wicki J, Olivieri J, Pizzolato G, et al.: Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) 1999, 38:183-185.
53. Mouthon L, Deblois P, Sauvaget F, et al.: Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy. Am J Nephrol 1995, 15:266-269.
54. Darras-Joly C, Lortholary O, Cohen P, et al.: Regressing microaneurysms in 5 cases of hepatitis B virus related polyarteritis nodosa. J Rheumatol 1995, 22:876-880.
55. Molloy PJ, Friedlander L, Van Thiel DH, et al.: Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa. Hepatogastroenterology 1999, 46:2529-2531.
56. Sonntag KC, Schwarz-Eywill M, Hunstein W: Is interferon alpha a therapy for hepatitis B-associated polyarteritis nodosa? Br J Rheumatol 1995, 34:486-487.
57. Kruger M, Boker KH, Zeidler H, et al.: Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997, 26:935-939.
58. Travis SP, Czajkowski M, McGovern DP, et al.: Treatment of intestinal Behcet's syndrome with chimeric tumor necrosis factor alpha antibody. Gut 2001, 49:725-728.
59. Hassard PV, Binder SW, Nelson V, et al.: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: A case report. Gastroenterology 2001, 120:995-999.
60. Rozenbaum M, Rosner I, Portnoy E: Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002, 61:283-284.
61. Goossens PH, Verburg RJ, Breedveld FC: Remission of Behcet's syndrome with tumor necrosis factor alpha blocking therapy. Ann Rheum Dis 2001, 60:637.
62. Robertson LP, Hickling P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford) 2001,40:473-474.
63. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296. Five patients with relapsing Behcet-related uveitis were treated with infliximab. Visual acuity improved within 24 hours and complete suppression of ocular inflammation was seen 7 days after treatment in all patients. Interpretation of these findings is limited by short follow-up of 28 days.
64. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al.: Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001, 358:1644.
65. Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998, 134:1010-1016. Review of 22 articles published between 1986-1997 where IFN-α was used to treat Behcet disease. The authors applied standardized definitions of remission and disease activity to this body of literature to examine the overall findings.
66. Alpsoy E, Durusoy C, Yilmaz E, et al.: Interferon alfa-2a in the treatment of Behcet disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467-471. Randomized placebo-controlled trial of IFN-α in 23 patients with Behcet disease. This remains the most rigorous data to date although sample sizes are small, particularly for assessing the response of more severe manifestations.